Medicortex Finland is dedicated to improving the diagnostics of Traumatic Brain Injury (TBI). The company's focus is on the development of biomarker diagnostic kit for detection of concussion and traumatic brain injury. In the current campaign, Medicortex proposes a parallel project: development of a portable device that is able to quantitatively detect concussion and traumatic brain injuries from urine samples. In future, Medicortex's goal is to expand to the development of an innovative drug to halt the aggravation of brain injury.
Medicortex Finland Oyj was founded in June 2014 and is located in Werstas bioincubator in the heart of Turku Science Park. The company has received funding from Business Finland, twice from United States Department of Defense, Horizon-2020 innovation grant and the Finnish ELY-center (The Centre for Economic Development, Transport and the Environment), as well as from private investors.
Our nearest aim is to develop a handheld quick diagnostic kit for detection of concussions. The kit is based on the proprietary biomarker we have studied in several clinical trials. In parallel, Medicortex proposes development of a quantitative detection test, in collaboration with Fepod Oy Ltd, for the same indication.